Velocity Expands with Three New Greenfield Clinical Research Sites in the UK
Velocity Clinical Research, a leading multi-specialty clinical sites business, has announced the opening of three new greenfield clinical research sites in Bristol, Leicester, and Romford, showcasing the company's commitment to the UK market. This expansion comes at a time when clinical trial activity in the UK has experienced a decline in recent years. The number of patients enrolled in commercial clinical trials in the UK has decreased by 44% between 2017-18 and 2021-22.
Growth and Commitment to Sponsors and CROs
Velocity's growth in the UK and Europe is accelerating, with a total of nine sites. The addition of these three new sites demonstrates Velocity's dedication to providing clinical trial solutions for sponsors and contract research organizations (CROs). By setting up their own sites in the UK, Velocity aims to deliver faster start-up, greater efficiency, and quicker data delivery compared to traditional NHS and university-based research.
Principal Investigators and Enrolment Plans
Velocity Romford has already started training staff and plans to enroll patients into studies this month, led by Shilpa Muthusamy, MD. Velocity Bristol and Velocity Leicester expect to start enrolling patients at the end of October, with Matt Fisher, MD leading the latter site. The Principal Investigator for Bristol's site will be announced in due course.
Centralized Infrastructure and Global Access
With over 80 locations globally and access to more than 220 principal investigators and one million patients, Velocity offers fully integrated sites with a centralized infrastructure and common technology backbone. This enables superior patient enrollment and consistent, high-quality data delivery. CROs and biopharma companies can benefit from simplified access to international clinical research through Velocity's unified research site solutions.
In conclusion, Velocity's expansion in the UK signifies their commitment to providing efficient and high-quality clinical trial solutions, offering new opportunities for sponsors, CROs, and patients alike.
Implications of Velocity's Expansion for New Businesses in the UK
Velocity Clinical Research's expansion with three new greenfield clinical research sites in the UK sends a strong signal to new businesses in the healthcare and clinical research sectors. Despite a decline in clinical trial activity in the UK in recent years, Velocity's commitment to the UK market demonstrates the potential for growth and innovation in this space.
Opportunities for Collaboration and Innovation
The addition of these sites opens up opportunities for sponsors and CROs to collaborate with Velocity, potentially leading to faster start-ups, greater efficiency, and quicker data delivery. This could be a game-changer for new businesses looking to conduct clinical trials in the UK, offering them an alternative to traditional NHS and university-based research.
Impact on Patient Enrollment and Data Delivery
Velocity's centralized infrastructure and global access could also impact patient enrollment and data delivery. With over 80 locations globally and access to more than 220 principal investigators and one million patients, Velocity's unified research site solutions could simplify international clinical research for new businesses.
In conclusion, Velocity's expansion in the UK could reshape the landscape of clinical research in the region, offering new opportunities and challenges for businesses in this sector.
.svg)
